Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey by Bogdanet, Delia et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Follow-up at 1year and beyond of women with gestational diabetes
treated with insulin and/or oral glucose-lowering agents: a core outcome
set using a Delphi survey
Author(s) Bogdanet, Delia; Reddin, Catriona; Macken, Esther; Griffin, Tomas P.;
Fhelelboom, Narjes; Biesty, Linda; Thangaratinam, Shakila; Dempsey,
Eugene M.; Crowther, Caroline; Galjaard, Sander; Maresh, Michael;
Loeken, Mary R.; Napoli, Angela; Anastasiou, Eleni; Noctor, Eoin; de
Valk, Harold W.; van Poppel, Mireille N. M.; Agostini, Andrea;
Clarson, Cheril; Egan, Aoife M.; O'Shea, Paula M.; Devane, Declan;
Dunne, Fidelma P.
Publication date 2019-07-04
Original citation Bogdanet, D., Reddin, C., Macken, E., Griffin, T.P., Fhelelboom, N.,
Biesty, L., Thangaratinam, S., Dempsey, E., Crowther, C., Galjaard, S.
and Maresh, M. (2019) 'Follow-up at 1 year and beyond of women with
gestational diabetes treated with insulin and/or oral glucose-lowering
agents: a core outcome set using a Delphi survey'. Diabetologia, 62(11),
pp. 2007-2016. doi:10.1007/s00125-019-4935-9
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://link.springer.com/article/10.1007%2Fs00125-019-4935-9
http://dx.doi.org/10.1007/s00125-019-4935-9
Access to the full text of the published version may require a
subscription.
Rights © The Author(s) 2019. This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and
indicate if changes were made.
https://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/8963
Downloaded on 2020-06-06T01:02:31Z

ARTICLE
Follow-up at 1 year and beyond of women with gestational diabetes
treated with insulin and/or oral glucose-lowering agents: a core
outcome set using a Delphi survey
Delia Bogdanet1 & Catriona Reddin1 & Esther Macken1 & Tomas P. Griffin1 & Narjes Fhelelboom1 & Linda Biesty1 &
Shakila Thangaratinam2 & Eugene Dempsey3 & Caroline Crowther4 & Sander Galjaard5 & Michael Maresh6 &
Mary R. Loeken7,8 & Angela Napoli9 & Eleni Anastasiou10 & Eoin Noctor11 & Harold W. de Valk12 &
Mireille N. M. van Poppel13 & Andrea Agostini14 & Cheril Clarson15,16 & Aoife M. Egan17 & Paula M. O’Shea1 &
Declan Devane1 & Fidelma P. Dunne1
Received: 28 January 2019 /Accepted: 21 May 2019
# The Author(s) 2019
Abstract
Aims/hypothesis Gestational diabetes mellitus (GDM) is linked with a higher lifetime risk for the development of impaired
fasting glucose, impaired glucose tolerance, type 2 diabetes, the metabolic syndrome, cardiovascular disease, postpartum de-
pression and tumours. Despite this, there is no consistency in the long-term follow-up of women with a previous diagnosis of
GDM. Further, the outcomes selected and reported in the research involving this population are heterogeneous and lack
standardisation. This amplifies the risk of reporting bias and diminishes the likelihood of significant comparisons between
studies. The aim of this study is to develop a core outcome set (COS) for RCTs and other studies evaluating the long-term
follow-up at 1 year and beyond of women with previous GDM treated with insulin and/oral glucose-lowering agents.
Methods The study consisted of three work packages: (1) a systematic review of the outcomes reported in previous RCTs of the
follow-up at 1 year and beyond of women with GDM treated with insulin and/or oral glucose-lowering agents; (2) a three-round
online Delphi survey with key stakeholders to prioritise these outcomes; and (3) a consensus meeting where the final COS was
decided.
Results Of 3344 abstracts identified and evaluated, 62 papers were retrieved and 25/62 papers were included in this review. A
total of 121 outcomes were identified and included in the Delphi survey. Delphi round 1 was emailed to 835 participants and 288
(34.5%) responded. In round 2, 190 of 288 (65.9%) participants responded and in round 3, 165 of 190 (86.8%) participants
responded. In total, nine outcomes were selected and agreed for inclusion in the final COS: assessment of glycaemic status;
diagnosis of type 2 diabetes since the index pregnancy; number of pregnancies since the index pregnancy; number of pregnancies
with a diagnosis of GDM since the index pregnancy; diagnosis of prediabetes since the index pregnancy; BMI; post-pregnancy
weight retention; resting blood pressure; and breastfeeding.
Conclusions/interpretation This study identified a COS that will help bring consistency and uniformity to outcome selection and
reporting in clinical trials and other studies involving the follow-up at 1 year and beyond of women diagnosed with GDM treated
with insulin and/or oral glucose-lowering agents during pregnancy.
Keywords Core outcome set . Gestational diabetesmellitus . Insulin . Oral hypoglycaemic agents
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Introduction
The prevalence of gestational diabetes mellitus (GDM) is in-
creasing worldwide and ranges between 5.2% and 40.4%
across countries; this wide variability reflects multiple factors
such as BMI, ethnicity, country income, and also the diagnos-
tic criteria used [1]. Based on the International Association of
Diabetes in Pregnancy Study Group (IADPSG) criteria, the
European prevalence of GDM is approximatively 13% [2,
3]. Medical nutritional therapy (diet and exercise) is the first
step in the treatment of GDM [4]. However, if the desired
glycaemic goals are not achieved, pharmacological treatment
will be required.
GDM is linked with a substantial lifetime risk of develop-
ing type 2 diabetes. A meta-analysis conducted on studies
published over the last 50 years showed that women with a
history of GDM have a higher risk of developing type 2 dia-
betes (RR 7.4) compared with women with normal glucose
tolerance (NGT) in pregnancy [5]. Women with previous
GDM are more likely to develop the metabolic syndrome [6]
and cardiovascular disorders [7] in later life. Several studies
have shown that women with GDM have a higher risk of
developing postpartum depression [8, 9]. There is also a
growing body of literature associating a history of GDM with
the development of tumours, particularly breast and endome-
trial tumours [10].
Women with GDM should be screened for persistent dia-
betes or impaired fasting glucose and/or impaired glucose
tolerance at 6–12 weeks postpartum using non-pregnancy
criteria [11]. However, there is no standardised approach to
the long-term follow-up of women with a previous GDM
diagnosis. The results of clinical trials evaluating comparable
interventions are usually summarised in systematic reviews
and meta-analyses that provide the basis for guidelines and
treatment recommendations. However, there is little consis-
tency in outcome selection and reporting in clinical trials in-
volving this population. This inconsistency raises concern for
possible outcome selection bias, makes significant research
synthesis difficult and limits the ability to combine the find-
ings of individual studies into summary estimates. One way to
overcome this is to develop a core outcome set (COS).
A COS is the minimum set of outcomes that should be
consistently measured and reported in all clinical trials (and
other studies). However, this does not restrict researchers from
adding additional outcomes. A minimum set of outcomes will
provide greater uniformity of reporting in clinical trials and
more data to impact meta-analyses. Also, a COS will reduce
study heterogeneity and the risk of reporting bias by consis-
tently measuring and reporting these outcomes.
The Core Outcome Measures in Effectiveness Trials
(COMET) initiative aims to standardise outcome reporting
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in trials, facilitates participation of diverse experts undertaking
research and minimises duplication of work [12, 13]. The
Core Outcome Set STAndards for Reporting (COS-STAR) is
a checklist designed to be applicable regardless of the consen-
sus methods used to develop the COS and the various partic-
ipant groups [14]. The COS-STAR checklist provides guid-
ance for minimal COS study reporting and its purpose is to
promote the transparency and completeness of reporting in all
COS studies. The CoRe Outcomes in Women’s and Newborn
health (CROWN) initiative encourages the development of
COSs in women’s and newborns’ health.
The aim of this study was to develop a COS for trials and
other studies evaluating the long-term follow-up at 1 year and
beyond of women with previous GDM treated with insulin
and/oral glucose-lowering agents. This study focuses only
on women with GDM treated with insulin and oral glucose-
lowering agents as this population has more severe glucose
abnormalities and are more likely to progress to type 2 diabe-
tes, obesity and the metabolic syndrome [15, 16].
Methods
This study is registered in the COMET database [17]. Ethical
approval for the study was obtained from the Galway University
Hospitals Research Ethics Committee (reference CA 1905).
The three work packages of the study were: (1) a system-
atic review of literature that identified all the outcomes report-
ed in clinical trials that involved the long-term follow-up of
this population; (2) a Delphi survey in which all outcomes
were scored and prioritised by key stakeholder groups to pro-
vide a preliminary list of final outcomes; and (3) a consensus
meeting where the final list of outcomes was decided.
Systematic review Using a broad-based search strategy, the fol-
lowing databases were searched for relevant studies between
October 2017 and February 2018: Cochrane Central Register
of Controlled Trials (CENTRAL), the Cumulative Index to
Nursing and Allied Health Literature (CINAHL), PubMed,
EMBASE and Web of Science. ClinicalTrials.gov was also
searched for relevant ongoing trials. The reference lists of all
included studies were searched for additional studies not
retrieved from the electronic database search. There was no
time restriction on the date of publication of the studies. There
was no language restriction applied to the search strategy. Only
RCTs and RCT follow-up studies were included in the system-
atic review (an example of the search strategy is presented in the
electronic supplementary material [ESM] Methods).
In step 1, all identified study titles were reviewed and inel-
igible studies excluded (F.P. Dunne and D. Bogdanet). In step
2, the remaining studies were appraised by two reviewers (F.P.
Dunne and D. Bogdanet) who independently assessed the ti-
tles and abstracts of each study included at this stage. Full
texts of studies meeting the inclusion criteria and studies for
which there was uncertainty regarding inclusion at the title/
abstract screening stage were retrieved and reviewed indepen-
dently (F.P. Dunne and D. Bogdanet). The same two authors
extracted the data independently, reviewed the data together,
assessed consensus and ensured that all outcomes were iden-
tified. Following review by F.P. Dunne, D. Devane, D.
Bogdanet, L. Biesty, A. M. Egan and P. M. O’Shea (the study
advisory group [SAG]), extracted outcomes were grouped un-
der the following domains: laboratory tests, clinical condi-
tions, physiological variables, diet and exercise, psychological
variables and other.
Delphi method We conducted a three-round eDelphi survey
[18]. This facilitated international participation. Questionnaires
were completed online using SurveyMethods software (www.
surveymethods.com, SurveyMethods, Dallas, TX, USA,
accessed 9 May 2018). Full details of our methods are given in
Bogdanet et al (2019) [19] and are described briefly below.
The stakeholder groups comprised: women with a previous
diagnosis of GDM, endocrinologists, diabetes nurses, obste-
tricians, midwives, paediatricians, neonatologists, general
practitioners, practice nurses, dietitians, physiotherapists, re-
searchers with expertise in gestational diabetes, policy makers
and others (which included clinicians with expertise in gesta-
tional diabetes from specialties other than endocrinology and
obstetrics, epidemiologists, clinical biochemists and
healthcare assistants).
Invitation emails were sent to societies and individual mem-
bers of the IADPSG, Diabetes Ireland, Irish Endocrine Society
(IES), IDF, International Federation of Gynecology and
Obstetrics (FIGO), European Board and College of Obstetrics
and Gynaecology (EBCOG), Irish Nutrition and Dietetic
Institute (INDI), Association of Clinical Biochemists in Ireland
(ACBI), Irish Institute of Obstetricians and Gynaecologists,
Saolta Healthcare Group (Ireland), EASD, Diabetic Pregnancy
Study Group (DPSG) of the EASD and the Royal College of
Physicians Ireland (RCPI) (divisions of Endocrinology,
Obstetrics and Endocrinology and Paediatrics). All participants
were asked to forward the invitation to others whom they
regarded as having the required expertise. Additionally, women
with a history of GDMwere contacted through their clinic by the
authors and by additional study participants and, following con-
sent, were forwarded the survey link or given a printed form of
the survey. Women with GDM were from a number of clinics;
the final group who participated in the consensus meeting were
from the Galway clinic.
Study participants gave informed consent prior to the sub-
mission of any answers and the following information was
also requested: name, email address, sex, stakeholder group
and country of residence. Participants were given information
about the study and about COSs. Participants were encour-
aged to complete the eDelphi questionnaire in each round.
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An email reminder was sent to anyone who did not respond
after 7 and 14 days and also 3 days and 1 day before the end of
the round.
In the first round of the survey, all the outcomes identified
in the systematic review were presented to the participants
grouped by domain. The study participants were asked to rate
each outcome on a nine-point Likert scale (1–3 limited impor-
tance; 4–6 important but not critical, 7–9 critical). We provid-
ed all participants with plain English explanations of the out-
comes included in the survey. Participants were invited to
suggest additional relevant outcomes (no limit to the number
of outcomes suggested) using free-text responses. If two or
more study participants nominated an outcome, that outcome
was included in round 2 of the survey.
All stakeholder groups were grouped into three broader
groups, i.e. clinicians, women with a previous diagnosis of
GDM and researchers/policy makers. Descriptive statistics
were used to summarise the results from round 1. We sent
individual results, the results of each stakeholder group and
the results of the total group to each study participant. All
outcomes including the additional outcomes suggested in
round 1 (by two or more participants) were carried forward
to round 2. All respondents to round 1 were invited to partic-
ipate in round 2 and asked to re-rate the outcomes. All out-
comes that scored 7–9 on the Likert scale in ≥70% of answers
and 1–3 in <15% of answers were carried forward to round 3.
Each participant who completed round 2 was emailed their
individual results and the results of each stakeholder group
and the total group and was invited to participate in round 3
and re-score retained outcomes. Outcomes were classified as
‘consensus in’ (≥70% participants scoring as 7–9 and <15%
scoring as 1–3) or ‘consensus out’ (≥70% scoring as 1–3 and
<15% scoring as 7–9). The ‘consensus in’ and borderline out-
comes were brought forward to the consensus meeting.
Consensus meeting The consensus meeting involved repre-
sentatives from each stakeholder group. The participants
discussed each outcome brought forward from round 3. If
necessary, the outcomes were grouped or renamed in order
to facilitate dissemination and usefulness. At the end of the
discussion, each participant voted ‘outcome in’ or ‘outcome
out’ using the app Poll Everywhere (San Francisco, CA, USA,
accessed 27 September 2018) on their electronic device, thus
concealing their identity. Outcomes that scored over 70%
‘outcome in’, were included in the final COS.
Results
A total of 3344 titles and abstracts were identified. Following
review of the title and/or abstracts, 62 full text papers were re-
trieved and assessed for eligibility. A further 37 papers were
excluded following full text assessment, leaving 25 papers in
the review (ESM Table 1). Following data extraction, 121 indi-
vidual outcomes were identified. Following the SAG meeting,
similar outcomes were combined, leaving a final 116 outcomes
to be grouped and included in round 1 (ESM Fig. 1).
The first round of the Delphi survey was sent to 835 par-
ticipants (societies and individual members). At the end of
round 1, there were 288 respondents (34.5%) representing
33 countries and five continents (Table 1). A total of 73% of
the respondents were female. The distribution of answers
throughout the stakeholder groups in each of the three rounds
is presented in Table 1. An additional ten outcomes were sug-
gested by two or more study participants and were included in
round 2 (ESM Table 2).
Round 2 participants were asked to rate 126 outcomes
grouped as described in the Methods section. Round 2 was
completed by 65.9% of the round 1 responders (190 partici-
pants). Similar to round 1, there was a female predominance
among responders (73.7%). The distribution of answers amid
stakeholder groups was similar to round 1 (Table 1) (clinicians
82.6%, women with a history of GDM 10%, researchers/
policy makers 7.4%). All outcomes that scored 7–9 on
Likert scale in ≥70% and 1–3 in <15% by study participants
were brought forward to round 3 (n = 34). The percentage of
participants who voted 1–3, 4–6 or 7–9 on each outcome at the
end of round 2 is presented in Table 2.
Round 3 was completed by 165 participants (86.8%).
Similar to round 2, outcomes were brought forward when
70% or more participants scored the outcome as 7–9 and
<15% participants scoring as 1–3. In total, 30 outcomes went
through the consensus meeting (ESM Table 3).
Consensus meeting The consensus meeting involved 20 par-
ticipants, a chairperson and an administrator. The stakeholder
groups included four women with a history of gestational
diabetes, one diabetes nurse specialist, two midwives, one
policy maker, two paediatricians, one clinical biochemist,
two researchers in the area of diabetes in pregnancy, one ep-
idemiologist, two obstetricians and four endocrinologists. The
participants represented ten countries and three continents.
Before the discussion on each outcome, the participants were
shown the previous voting results on that particular outcome
by the total group and by each stakeholder group. Each out-
come was discussed and there was agreement that some items
should be grouped and/or rephrased. Therefore, ‘75 g oral
glucose tolerance test’, ‘Blood glucose level at 2 h during
the 75 g oral glucose tolerance test’, ‘Fasting glucose’ and
‘HbA1c blood levels’ were combined into ‘Assessment of
glycaemic status’. ‘Type 2 diabetes’ became ‘Diagnosis of
type 2 diabetes since the index pregnancy’. ‘GDM in
subsequent/future pregnancies’ became ‘Number of pregnan-
cies with a diagnosis of GDM since the index pregnancy’.
‘Impaired fasting glucose’ and ‘Impaired glucose tolerance’
were combined into ‘Diagnosis of prediabetes since the index
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pregnancy’ and ‘Breastfeeding after the index pregnancy’ be-
came ‘Breastfeeding’.
Following discussion, the panel voted on each outcome to
determine whether it should or should not be included in the
final set. The final COS included nine outcomes and is pre-
sented in Table 3, together with the percentage of participants
that voted ‘consensus in’.
Discussion
This study used robust methods to develop the first COS relevant
to the follow-up of women with previous gestational diabetes
treated with insulin and/or glucose-lowering agents. A Delphi
consensus panel with 20 representatives from ten countries
agreed on nine outcomes to be included in the final COS. It is
Table 1 Characteristics of participants in the Delphi online survey
Variable Round 1, % (n = 288) Round 2, % (n = 190) Round 3, % (n = 165)
Sex (female) 73 73.7 72.1
Experience/background
Diabetes nurse specialist 5.5 6.3 5.5
Endocrinologist 31.2 35.8 36.4
Obstetrician 14.2 15.8 17.6
Paediatrician 1.7 2.1 0.6
Neonatologist 1.7 1.6 1.2
Midwife 5.5 4.7 4.8
General practitioner 3.8 3.1 3
Practice nurse 0.3 0.5 0.6
Dietitian 1.7 1 0.6
Physiotherapist 1 0 0
Other 11.8 11.6 12.1
Woman with previous diagnosis of GDM 14.2 10 10.3
Researcher with expertise in diabetes 5.5 5.8 6.1
Policy maker 1.4 1.6 0.6
Clinician 78.9 82.6 83.3
Health service user 14.2 10 10.3
Researcher/policy maker 6.9 7.4 6.7
Participant’s country of residence
Albania 0.3 0.5 0.6
Argentina 7.3 6.8 6.7
Australia 3.1 4.2 3.6
Austria 0.7 1.1 1.2
Belgium 1 0.5 0.6
Canada 1 1.6 1.8
Chile 0.3 0.5 0.6
Croatia 0.7 1.1 1.2
Czech Republic 0.3 0 0
Denmark 3.8 4.2 4.8
France 1.3 2.1 2.4
Germany 1 0.5 0.6
Greece 0.7 1.1 0.6
Hungary 0.3 0 0
India 0.7 0.5 0.6
Ireland 49.8 47.4 49
Israel 0.7 0 0
Italy 2.1 2.6 2.4
Jamaica 0.3 0.5 0.6
Lithuania 1.4 1.6 1.8
Malta 0.3 0.5 0.6
The Netherlands 0.7 1.1 0.6
New Zealand 3.8 4.2 3
Nigeria 0.3 0.5 0.6
Poland 0.7 0 0
Portugal 0.3 0.5 0
Romania 0.7 1.1 1.2
Spain 2.1 1.1 1.2
Sweden 1 1.1 0.6
UAE 0.7 0.5 0.6
UK 7.4 6.4 4.8
USA 4.2 5.8 6.8
Uruguay 0.3 0.5 0
UAE, United Arab Emirates
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Table 2 Percentage of round 2 participants (n = 190) scoring each outcome as 1–3, 4–6 or 7–9 on the 9-point Likert scale
Variable Score 1–3, % Score 4–6, % Score 7–9, %
Laboratory tests
75 g OGTT 5 11 84
Glucose level at 30 min during the 75 g OGTT 53 28 19
Glucose level at 1 h during the 75 g OGTT 24 23 53
Glucose level at 2 h during the 75 g OGTT 7 14 79
Glucose level at 3 h during the 75 g OGTT 58 28 14
Insulin level at 30 min during the OGTT 53 31 16
Insulin level at 2 h during the OGTT 39 37 24
Fasting glucose 3 15 82
Random glucose 45 36 19
HbA1c level 4 13 83
Fasting HbA1c 50 20 30
Insulin level 38 34 28
Fasting insulin level 28 36 36
Insulin to glucose ratio 28 40 32
Insulinogenic index 30 42 28
Corrected insulin response 37 40 23
Insulin sensitivity 25 41 33
HOMA 29 42 29
HOMA-IR 26 39 35
HOMA-β 28 40 32
Triacylglycerol level 24 36 40
Fasting triacylglycerol level 12 33 55
Cholesterol level 21 37 42
Fasting cholesterol 14 37 49
HDL 20 36 44
Fasting HDL 15 38 47
LDL 20 33 47
Fasting LDL 16 36 48
Apo-lipoprotein B 35 46 19
Oxidised lipoproteins 38 46 16
ACR 11 37 52
Insulin growth factor 45 39 16
IGF-binding protein 3 level 50 37 13
Paraoxonase 54 33 13
Leptin 40 40 20
Adiponectin 39 42 19
Total circulating adiponectin 43 42 15
High sensitivity C-reactive protein 35 45 20
Fibrinogen 47 39 14
Alanine aminotransferase 23 46 31
Thyroid stimulating hormone 16 40 44
Free thyroxine 28 35 37
Total tissue plasminogen activator antigen 49 39 12
Cytokines 47 41 12
Genotype for Pro12Ala polymorphism 57 33 10
Plasma uric acid 41 38 21
γ-glutamyl aminotransferase 30 43 27
Vitamin D 26 42 32
Clinical conditions
Type 2 diabetes 0 3 97
Insulin-treated type 2 diabetes 3 8 89
GDM in subsequent pregnancies 0 4 96
The metabolic syndrome 2 16 82
Impaired fasting glucose 2 14 84
Impaired glucose tolerance 2 14 84
Polycystic ovary syndrome 4 26 70
Cardiovascular disease 2 17 81
Physiological variables
Weight 1 4 95
Height 12 12 76
BMI 1 13 86
Waist circumference 2 18 80
Hip circumference 9 34 57
Waist/hip ratio 7 28 65
Body fat 8 37 55
Lean mass 7 45 48
Post-pregnancy weight retention 2 24 74
BP 1 11 88
Resting BP 2 15 83
Systolic BP 2 12 86
Diastolic BP 2 12 86
Resting pulse 6 38 56
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advised that all studies in this area use this COS to facilitate
comparison among studies and limit heterogeneity and reporting
bias. The application of agreed methods in developing a COS
and the participation of multiple stakeholder groups assure the
wide applicability and dissemination of this COS.
The wide applicability of the study was one of the main
reasons why the outcomes ‘75 g oral glucose tolerance test’,
‘Blood glucose level at 2 h during the 75 g oral glucose
tolerance test’, ‘Fasting glucose’ and ‘HbA1c blood levels’
were combined into ‘Assessment of glycaemic status’; in so
doing, the COS permits researchers the opportunity to assess
glycaemic status according to their own national guidelines
and resources. In addition, this COS identifies ‘what is to be
collected’ and not ‘how it is to be collected’, which will be the
subject of future work. Similarly, ‘Impaired fasting glucose’
and ‘Impaired glucose tolerance’ were combined as
Table 2 (continued)
Variable Score 1–3, % Score 4–6, % Score 7–9, %
Diet and exercise
Coffee intake 22 56 22
Tea intake 25 55 20
Alcohol intake 5 32 63
Protein intake 12 45 43
Carbohydrate intake 8 27 65
Fruit intake 10 28 62
Vegetable intake 9 29 62
Dairy intake 8 39 52
Fat intake 10 32 58
Fibre intake 9 38 53
Low glycaemic intake 10 35 55
Unsaturated fat intake 13 32 55
Saturated fat intake 12 31 57
Healthy fat intake 14 29 57
Low fat intake 18 40 42
Low carbohydrate high-fat diet 17 37 46
Nutrition composition 13 34 53
Food frequency 13 29 58
Portion size 7 27 66
Total caloric intake 7 26 67
Sweetened beverage intake 9 23 68
Physical activity 2 9 89
Walking/cycling to work 7 23 70
Time spent sitting 6 23 71
Time spent sleeping 9 26 65
Psychological variables
Quality of life 3 18 79
Eating behaviour 6 24 70
Adverse emotional status 4 28 68
Mental health status 4 23 73
Anxiety 4 30 66
Depression 4 23 73
Activity to enhance mood 8 28 64
Postnatal depression 5 15 80
Other
Smoking status 4 7 89
Quality adjusted life year 6 30 64
Healthcare costs 11 30 59
Lost productivity due to absence from work 11 39 50
Sickness resulting in absence from work 11 37 52
Satisfaction with research participation 15 41 44
Number of pregnancies since the index pregnancy 6 17 77
Health insurance 25 38 37
Income 20 40 40
Menopause status 17 35 48
Miscarriage after the index pregnancy 11 29 60
Breastfeeding in the index pregnancy 5 16 79
Breastfeeding at 1 year post delivery 10 28 62
Plans for future pregnancies 10 24 66
Employment status 21 35 44
Return to work after pregnancy 18 41 41
Current medications 5 21 74
Oral contraceptive use 14 23 63
Contraception method 16 27 57
Hormone replacement therapy 16 30 44
Hysterectomy 25 35 40
Oophorectomy 26 37 47
Genital malignancies 20 30 40
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‘Diagnosis of prediabetes since the index pregnancy’ to give
the COS a worldwide applicability in light of the variability in
diagnostic tools and criteria. However, while we would rec-
ommend that collection and reporting of all outcomes in the
COS is mandatory, researchers can choose to collect any ad-
ditional outcomes required for their study, including specific
indices of glycaemic control.
Of importance, the COS consensus meeting had representa-
tion from a variety of health professionals/specialties, both local
and international, and includedwomenwith a previous diagnosis
of GDM. This stakeholder composition permitted both the health
professionals and women to bring their experience and perspec-
tives to the issues under discussion. Each participant was able to
have an understanding of what was important to the other person
and what was feasible. Ultimately, this resulted in shared
decision-making in a study that will impact future research of
women with gestational diabetes.
There are some limitations to our study. Currently, there are no
methods for sample size calculation for this type of study. To
minimise the potential for selection bias, participantswere invited
through international organisations and personal professional
email lists. Only participants who completed each survey round
were recorded. From the totality of initial emails sent before
round 1, we had a 35% response. This response rate, however,
included participants from 33 countries and five continents. We
had a 34% drop-off rate between round 1 and round 2, but,
impressively, 87% of participants who completed round 2 also
completed round 3. There was a low response rate among pri-
mary care physicians (3.5%).
Another potential limitation of this study is the large number
of items to be scored in rounds 1 and 2 of the online Delphi
survey, which may have impacted negatively on the survey re-
sponse rate.
We had a large percentage of international participants, includ-
ing individuals from high-income, upper- and lower-middle-
income countries. However, low-income countries were under-
represented, and this may limit the generalisability of this COS
to certain parts of the world. The participants at the consensus
meeting tried to overcome this by rephrasing or combining out-
comes in order to increase theworldwide applicability of the COS.
The access to service users was limited by data protection
laws, so participants were recruited through the clinical facilities.
Despite this, 30% of respondents in round 1 were international
service users. At the consensus meeting, 50% of service user
participants were non-Irish.We sought international participation
for the COS to have global relevance. The service user represen-
tativesmade important suggestions on all the outcomes discussed
at the consensus meeting. Anonymous voting (via the electronic
app during this meeting) aimed to prevent participants feeling
compelled to vote in a certain way. It has been advocated that
the views of health service users should be given greater value in
the development of a COS [20] as outcomes reported for clinical
studies might not reflect endpoints that are meaningful for them.
Examples exist where health service users identified an outcome
important to them as a group thatmight not have been considered
by clinicians [21–23]. However, the responses from health ser-
vice users and the responses from other stakeholder groups were
generally concordant.
The strengths of the study include our use of robust
methods in the COS development, including adherence to
the COS-STAR statement, the thoroughness of the systematic
review (six databases were searched for relevant studies), the
high number of participants and the diversity of stakeholder
groups participating at each stage of the COS.
Recent review papers have shown the degree of outcome
reporting bias among studies, with the main outcome not be-
ing reported in up to 47% of the studies and inadequately
reported in up to 76% of the studies reviewed [24–26].
Therefore, there is a cogent argument for creating and dissem-
inating a COS to harmonise outcome reporting.
This is the first study to outline a COS for the long-term
follow-up of women with previous GDM. We encourage all
investigators undertaking research in this field to report, as a
minimum, this COS to reduce reporting bias by allowing evi-
dence synthesis across clinical studies. This will ultimately lead
to improvements in the quality of research and delivery of
evidence-based healthcare for women with GDM.
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Table 3 Final outcomes to be included in the COS
Outcome Votes for the outcome
to be included in the
final COS, %
Assessment of glycaemic status 100
Diagnosis of T2DM since the index pregnancy 90
Number of pregnancies since the
index pregnancy
100
Number of pregnancies with a diagnosis of GDM
since the index pregnancy
100
Diagnosis of prediabetes since the index
pregnancy
100
BMI 100
Post-pregnancy weight retention 95
Resting BP 100
Breastfeeding 75
T2DM, type 2 diabetes mellitus
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